carfilzomib
Selected indexed studies
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. (Lancet, 2021) [PMID:34097854]
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. (Lancet Oncol, 2016) [PMID:26671818]
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. (N Engl J Med, 2015) [PMID:25482145]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. (2021) pubmed
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. (2016) pubmed
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. (2015) pubmed
- Carfilzomib. (2013) pubmed
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. (2020) pubmed
- Carfilzomib in multiple myeloma. (2014) pubmed
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. (2018) pubmed
- Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. (2019) pubmed
- Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial. (2024) pubmed
- Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. (2021) pubmed